// App-Quantinova.ai

: Reversal of Anticoagulation in Patients on Rivaroxaban or Apixaban (DOAC) with Major Bleeding Episodes (MBE) with 4 Factor Prothrombin Complex Concentrates (PCC): A Multicentre Retrospective Study

Researchers

Presenter

  • B.E. Fan

Principal Investigators

  • C.A. Gallardo

  • H.M. Tay

  • E.S. Yap

  • M.L. Tung

  • S.H. Yeang

  • W.P.V. Tham

  • K.Y. Lee

  • H.C. Tay

  • I.Y.H. Loo

  • D.S.Y. Tan

  • Y.C. Lin

  • C.L.L. Sum

  • K.H. Ong

  • V.S. Sampath

Medical Centers

  • Tan Tock Seng Hospital, Department of Haematology, Singapore, Singapore

  • Khoo Teck Puat Hospital, Department of Laboratory Medicine, Singapore, Singapore

  • Singapore General Hospital, Department of Haematology, Singapore, Singapore

  • National University Cancer Institute, Department of HematologyOncology, Singapore, Singapore

  • Ng Teng Fong General Hospital, Laboratory Medicine, Singapore, Singapore

  • Singapore General Hospital, Singapore, Singapore

  • Khoo Teck Puat Hospital, Singapore, Singapore

Locations

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • Prothrombin

Drug/Treatment

  • Prothrombin complex

  • rivaroxaban

  • Hemostatic Solution

  • apixaban

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved